BioSpace News Archive

Revibe technologies, a commercial-stage digital therapeutics company, announced today the positive results of their feasibility study examining the efficacy of FokusRx in school aged children with attention deficit hyperactivity disorder (ADHD).

According to Emergen Research, the global cell-free DNA (cfDNA) testing market size was USD 4.79 billion in 2020 and is expected to reach USD 28.28 billion in 2028 and register a revenue CAGR of 26.2% during the forecast period, 2021-2028.

The global pharma & healthcare market report points out the key trends and developments taking place in this business space in the ongoing COVID-19 times.

Comar, a premier supplier of custom medical devices & assemblies and specialty packaging solutions, announced today it has acquired Automatic Plastics Ltd., a contract manufacturer of injection molded products primarily for the medical device and pharmaceutical sectors.

ERYTECH Pharma announced the allowance of a US patent application covering arginine deiminase encapsulated into red blood cells for the treatment of arginase-1 deficiency, a debilitating rare metabolic disease.

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2021 financial results and provide a corporate update on February 15, 2022.

Gritstone bio, Inc. announced that the company’s Board of Directors has granted five employees nonqualified stock options to purchase an aggregate of 35,400 shares of its common stock with an exercise price of $5.46, which is equal to the closing price of Gritstone’s common stock on January 31, 2022, the grant date of the awards.

Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will participate in a fireside chat at the 11th Annual SVB Leerink Virtual Global Healthcare Conference.

Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), today announced that Lee Rauch has been appointed to the Company’s board of directors.

Inspire Medical Systems, Inc., a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, reported financial results for the quarter and full year ended December 31, 2021, and provided full year 2022 guidance.